The finalists for the 2025 Cambridge Independent Science and Technology Awards can now be revealed. It follows an extensive ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

根据最新的SEC文件显示，知名投资公司EcoR1 Capital, LLC在三天内大幅增持了Zymeworks Inc. (NASDAQ: ZYME )的股份，收购金额约为1310万美元。根据 InvestingPro 数据，这家制药公司目前市值为8.72亿美元，其现金储备超过债务。

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Strong employment in Vancouver's life sciences sector could support healthy levels of commercial real estate activity in the ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Zymeworks (NasdaqGS:ZYME) with a Outperform ...

Zymeworks Inc. (NASDAQ:ZYME) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus statutory numbers for both revenue ...

Zymeworks (NYSE:ZYME – Free Report) had its target price raised by Citigroup from $18.00 to $19.00 in a report released on ...

04. Zymeworks Inc. (ZYME) 2024年第四季度财报电话会议：Zymeworks是一家专注于开发多功能生物治疗药物的临床阶段生物技术公司，其2024年净亏损1.227亿美元，收入从2023年的7600万美元略增至7630万美元。公司拥有多个临床前和临床阶段的项目，包括ZW191（FRα靶向ADC）和ZW251（GPC3靶向ADC），后者在肝细胞癌模型中表现出色，预计2025年 ...

Gentleman has created a ranking of the best Italian red wines by cross-referencing the evaluations of the most important ...